Savient Pharmaceuticals appoints president of Savient Europe

David Veitch takes up the role

David Veitch took over as president of Savient Europe yesterday.

Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient's European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.

Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.

Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.

Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.

Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.

You may also like

Design & Build

Guardtech Group celebrates record 2025 with global cleanroom expansion

A landmark year sees mobile, modular and GMP cleanrooms delivered across healthcare, pharma and microelectronics
Pharmaceutical

Cytiva and Fida Biosystems unite to improve molecular insight for faster drug discovery

The collaboration will combine complementary and orthogonal approaches to simplify workflows and improve confidence in experimental results
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Subscribe now